Although Parkinson’s is thought of primarily as a movement disorder, memory is frequently affected, and this interferes with quality of life. This research aims to find tests — so called “biomarkers” — that are critical for developing new therapies to slow or even prevent memory loss. A pathway regulating an important type of brain lipids (fats in nerve cell membranes), termed sphingolipids, appears abnormal in Parkinson’s and will be monitored in blood. The goal is to develop a test for a “bad sphingolipid” useful for accelerating the development of medications to halt memory decline in patients.
Who can participate?
Patients with Parkinson’s disease and memory problems
Patients with dementia with Lewy bodies
What does it involve?
Four visits over two years
Parking will be validated. Compensation for optional CSF collection (once per year) is $200.
Interested in learning more?
Contact Yuliya Kuras, PhD: (857) 307-5424 or email@example.com